Parkinson's disease gene therapy - Oxford BioMedica

Drug Profile

Parkinson's disease gene therapy - Oxford BioMedica

Alternative Names: OXB-101; OXB-102; ProSavin; Tricistronic lentiviral vector encoding for TH, AADC and CH1 - Oxford BioMedica

Latest Information Update: 21 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Oxford BioMedica
  • Class Antiparkinsonians; Gene therapies
  • Mechanism of Action Dopamine release stimulants; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Parkinson's disease

Most Recent Events

  • 21 Sep 2015 Phase-I/II development for Parkinson's disease completed in France and the United Kingdom
  • 13 Mar 2015 Oxford BioMedica plans a phase I/II trial of OXB 102 for Parkinson's disease in United Kingdom
  • 05 May 2014 Oxford BioMedica receives a grant from the UK's Technology Strategy Board, under its Biomedical Catalyst funding programme, for Parkinson's disease gene therapy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top